washington  reuters    a u s  federal health agency said on wednesday it had  expressly advised  mylan nv  myl o  that the drugmaker had improperly classified its epipen emergency allergy treatment in a way that allowed it to pay lower rebates to state health programs  the disclosure comes as u s  lawmakers and prosecutors are investigating mylan over steep price hikes for the epipen device which have rendered the drug unaffordable for a growing number of families  a least one state has launched an investigation into whether mylan failed to pay proper rebates to the medicaid program for the poor  the centers for medicare and medicaid services  or cms  said in a statement it had  on multiple occasions  provided guidance to the industry and mylan on the proper classification of drugs and has expressly advised mylan that their classification of epipen for purposes of the medicaid drug rebate program was incorrect   cms  part of the u s  department of health and human services  declined to say what action it took to push for the misclassification to be corrected or when it spoke to mylan  mylan classified epipen with the medicaid drug rebate program as a generic treatment  which provides a rebate of  percent to state medicaid programs  rather than as a branded drug  which pays a minimum rebate of   percent   mylan has said it complied with cms rules  the company did not immediately respond to requests for comment on the cms statement  mylan has been heavily criticized for sharply raising the price of epipen devices  which are carried by people with life threatening allergies  mylan acquired the product in  and has raised the list price for a pair of epipens to   from about   in   earlier on wednesday  u s  senators richard blumenthal  charles grassley and amy klobuchar asked the u s  department of justice to investigate a possible misclassification   the facts     suggest that mylan may have knowingly misclassified epipens  potentially in violation of the false claims act and other statutes   the lawmakers said in a letter to attorney general loretta lynch  the false claims act is used to pursue companies that defraud the federal government  